Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic Strategies for Rheumatoid Arthritis
James R. O’Dell
New England Journal of Medicine (2004) Vol. 350, Iss. 25, pp. 2591-2602
Closed Access | Times Cited: 578

Showing 1-25 of 578 citing articles:

The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pál Pacher, Sándor Bátkai, George Kunos
Pharmacological Reviews (2006) Vol. 58, Iss. 3, pp. 389-462
Open Access | Times Cited: 1989
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
Mark C. Genovese, Jean‐Claude Becker, Michael Schiff, et al.
New England Journal of Medicine (2005) Vol. 353, Iss. 11, pp. 1114-1123
Open Access | Times Cited: 1206
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen, et al.
New England Journal of Medicine (2012) Vol. 367, Iss. 6, pp. 508-519
Open Access | Times Cited: 879
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
Eun Bong Lee, Roy Fleischmann, Stephen Hall, et al.
New England Journal of Medicine (2014) Vol. 370, Iss. 25, pp. 2377-2386
Open Access | Times Cited: 706
Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)
Suzanne Verstappen, Johannes W. G. Jacobs, M. J. van der Veen, et al.
Annals of the Rheumatic Diseases (2007) Vol. 66, Iss. 11, pp. 1443-1449
Open Access | Times Cited: 552
Strategies toward rheumatoid arthritis therapy; the old and the new
Mojtaba Abbasi, Mohammad Javad Mousavi, Sirous Jamalzehi, et al.
Journal of Cellular Physiology (2018) Vol. 234, Iss. 7, pp. 10018-10031
Closed Access | Times Cited: 357
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis
Valerie Nell
Annals of the Rheumatic Diseases (2005) Vol. 64, Iss. 12, pp. 1731-1736
Open Access | Times Cited: 341
Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: Results of a national prospective study
Yaël A de Man, Johanna M. W. Hazes, Hugo van der Heide, et al.
Arthritis & Rheumatism (2009) Vol. 60, Iss. 11, pp. 3196-3206
Closed Access | Times Cited: 337
State-of-the-art: rheumatoid arthritis: Figure 1
Iain B. McInnes, James R. O’Dell
Annals of the Rheumatic Diseases (2010) Vol. 69, Iss. 11, pp. 1898-1906
Closed Access | Times Cited: 300
British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years)
Raashid Luqmani, Sheena Hennell, C. Estrach, et al.
Lara D. Veeken (2009) Vol. 48, Iss. 4, pp. 436-439
Open Access | Times Cited: 297
Injectable Drug Delivery Systems for Osteoarthritis and Rheumatoid Arthritis
Maria Chiara Bruno, Maria Chiara Cristiano, Christian Celia, et al.
ACS Nano (2022) Vol. 16, Iss. 12, pp. 19665-19690
Closed Access | Times Cited: 91
Hydroxychloroquine and Risk of Diabetes in Patients With Rheumatoid Arthritis
Mary Chester Wasko, Helen B. Hubert, Vijaya Bharathi Lingala, et al.
JAMA (2007) Vol. 298, Iss. 2, pp. 187-187
Closed Access | Times Cited: 285
Host response modulation in the management of periodontal diseases
Giovanni E. Salvi, Niklaus P. Lang
Journal Of Clinical Periodontology (2005) Vol. 32, Iss. s6, pp. 108-129
Closed Access | Times Cited: 280
Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritis
Ken Coppieters, Torsten Dreier, Karen Silence, et al.
Arthritis & Rheumatism (2006) Vol. 54, Iss. 6, pp. 1856-1866
Open Access | Times Cited: 280
Antigen microarray profiling of autoantibodies in rheumatoid arthritis
Wolfgang Hueber, Brian Kidd, Beren H. Tomooka, et al.
Arthritis & Rheumatism (2005) Vol. 52, Iss. 9, pp. 2645-2655
Closed Access | Times Cited: 262
Treatment of rheumatoid arthritis
Angelo Gaffo, Kenneth G. Saag, Jeffrey R. Curtis
American Journal of Health-System Pharmacy (2006) Vol. 63, Iss. 24, pp. 2451-2465
Closed Access | Times Cited: 257
Nanobodies as novel agents for cancer therapy
Hilde Revets, Patrick De Baetselier, Serge Muyldermans
Expert Opinion on Biological Therapy (2005) Vol. 5, Iss. 1, pp. 111-124
Closed Access | Times Cited: 240
TNF-α Is a Critical Effector and a Target for Therapy in Antiphospholipid Antibody-Induced Pregnancy Loss
Jessica Berman, Guillermina Girardi, Jane E. Salmon
The Journal of Immunology (2005) Vol. 174, Iss. 1, pp. 485-490
Open Access | Times Cited: 222
Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study
Michael E. Weinblatt
Annals of the Rheumatic Diseases (2005) Vol. 65, Iss. 6, pp. 753-759
Open Access | Times Cited: 221
B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents
Axel Finckh, Adrian Ciurea, Laure Brulhart, et al.
Arthritis & Rheumatism (2007) Vol. 56, Iss. 5, pp. 1417-1423
Closed Access | Times Cited: 214
Comparison ofTripterygium wilfordiiHook F Versus Sulfasalazine in the Treatment of Rheumatoid Arthritis
Raphaela Goldbach‐Mansky
Annals of Internal Medicine (2009) Vol. 151, Iss. 4, pp. 229-229
Open Access | Times Cited: 214
SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis
Poh Kam Wong
Journal of Clinical Investigation (2006) Vol. 116, Iss. 6, pp. 1571-1581
Open Access | Times Cited: 207
The development of novel therapies for rheumatoid arthritis
Ling-dong Quan, Geoffrey M. Thiele, Jun Tian, et al.
Expert Opinion on Therapeutic Patents (2008) Vol. 18, Iss. 7, pp. 723-738
Open Access | Times Cited: 171
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
Axel Finckh, Adrian Ciurea, Laure Brulhart, et al.
Annals of the Rheumatic Diseases (2009) Vol. 69, Iss. 2, pp. 387-393
Open Access | Times Cited: 164
A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry
L.G. Schipper, Marloes Vermeer, H. H. Kuper, et al.
Annals of the Rheumatic Diseases (2011) Vol. 71, Iss. 6, pp. 845-850
Closed Access | Times Cited: 164
Page 1 - Next Page

Scroll to top